Search clinical trials for: exenatide extended-release

Total 6480 results

Vivani Medical, Inc
Medpace, Inc.

Not yet recruiting

Assessment of Safety, Tolerability and Drug Levels of NPM-119 in Participants With Type 2 Diabetes (LIBERATE-1)

Type 2 Diabetes
University College, London

Active, not recruiting

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease (Exenatide-PD3)

Parkinson's Disease

United Kingdom
Chinese University of Hong Kong

Recruiting

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (GAPP-SVD)

Cerebral Small Vessel Disease

Hong Kong
OPKO Health, Inc.

Completed

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico, Romania, Poland, Mexico, Greece
Vanderbilt University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

Diabetes Mellitus | Human Immunodeficiency Virus Infection

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
University of Minnesota

Completed

Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

Severe Obesity

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
University at Buffalo
AstraZeneca

Completed

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

Evaluate Ketogenic Stress

United States
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
University at Buffalo
AstraZeneca

Terminated

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes (1981)

Kidney Diseases | Type2 Diabetes

United States
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
AstraZeneca

Completed

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Type 2 Diabetes Mellitus

Canada, United States
LG Life Sciences

Unknown

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Anders Fink-Jensen, MD, DMSci
The Novavì outpatient clinics, Copenhagen; Neurobiology Research Unit, Rigshospitalet... and other collaborators

Completed

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence? (EXALT)

Addiction, Alcohol | Alcohol Dependence, in Remission

Denmark
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Johns Hopkins University
Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple University

Not yet recruiting

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Asthma | Overweight and Obesity | Asthma Chronic
The University of Texas Health Science Center,...
The Center for Clinical and Translational Sciences (CCTS) Clinical Research...

Completed

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Obesity | Prediabetes

United States
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Seroma

Italy
Methodist Healthcare

Completed

Envarsus XL Immunosuppression Following Liver Transplantation

Recipients of Liver Transplant

United States
Janssen-Cilag Ltd.,Thailand

Terminated

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (RONDO)

Detrusor Function, Overactive

Thailand
University of Arizona
National Cancer Institute (NCI)

Recruiting

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oral Leukoplakia | Erythroplakia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Lung Carcinoma

United States, Canada
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
McMaster University

Completed

Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

Insomnia | Hot Flashes | Major Depressive Disorder

Canada
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain

Low Back Pain
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Luye Pharma Group Ltd.
Parexel

Completed

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

Parkinson Disease

China
University of Colorado, Denver

Withdrawn

Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia

Trigeminal Neuralgia
AstraZeneca
Eli Lilly and Company

Completed

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Type 2 Diabetes Mellitus

Italy, Poland, Hungary, Mexico, Greece, Australia
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease

China
Beijing Anzhen Hospital
Novartis

Unknown

Fluvastatin AmelIorates aTHerosclerosis Study (FAITH)

Atherosclerosis | Coronary Heart Disease

China
University of Calgary
AstraZeneca

Completed

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Major Depressive Disorder

Canada
AstraZeneca
Eli Lilly and Company

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Alvogen Korea

Completed

Phase IV Study of Qsymia in Obese Patients

Obesity

Korea, Republic of

3

Subscribe